About Cencora, Inc.
https://www.cencora.comCencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S.
CEO
Robert P. Mauch PharmD
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2014-06-13 | Forward | 10:1 |
| 2009-06-16 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 660
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
BLACKROCK FUND ADVISORS
Shares:2.78M
Value:$973.73M
SECURITY CAPITAL RESEARCH & MANAGEMENT INC
Shares:1.35M
Value:$473.12M
BLACKROCK INSTITUTIONAL TRUST COMPANY, N.A.
Shares:1.05M
Value:$368.37M
Summary
Showing Top 3 of 72
About Cencora, Inc.
https://www.cencora.comCencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $83.73B ▲ | $2.94B ▲ | $-339.7M ▼ | -0.41% ▼ | $-1.75 ▼ | $149.56M ▼ |
| Q3-2025 | $80.66B ▲ | $2.04B ▲ | $687.4M ▼ | 0.85% ▼ | $3.55 ▼ | $1.27B ▼ |
| Q2-2025 | $75.45B ▼ | $2.02B ▲ | $717.87M ▲ | 0.95% ▲ | $3.7 ▲ | $1.32B ▲ |
| Q1-2025 | $81.49B ▲ | $1.85B ▼ | $488.6M ▲ | 0.6% ▲ | $2.52 ▲ | $963.1M ▲ |
| Q4-2024 | $79.05B | $2.31B | $3.38M | 0% | $0.02 | $459.25M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $4.36B ▲ | $76.59B ▲ | $74.84B ▲ | $1.51B ▼ |
| Q3-2025 | $2.23B ▲ | $73.96B ▲ | $71.98B ▲ | $1.98B ▲ |
| Q2-2025 | $1.98B ▼ | $71.19B ▲ | $70.18B ▲ | $1.01B ▲ |
| Q1-2025 | $3.22B ▲ | $69.05B ▲ | $68.83B ▲ | $226.58M ▼ |
| Q4-2024 | $3.13B | $67.1B | $66.46B | $645.94M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $-339.7M ▼ | $3.13B ▲ | $-321.94M ▼ | $-683.78M ▼ | $2.08B ▲ | $2.88B ▲ |
| Q3-2025 | $689.75M ▼ | $109.25M ▼ | $-234.69M ▲ | $215.48M ▲ | $96.76M ▲ | $-73.97M ▼ |
| Q2-2025 | $717.42M ▲ | $3.35B ▲ | $-4.08B ▼ | $-491.74M ▼ | $-1.22B ▼ | $3.22B ▲ |
| Q1-2025 | $488.6M ▲ | $-2.72B ▼ | $-343.04M ▼ | $3.21B ▲ | $97.09M ▲ | $-2.82B ▼ |
| Q4-2024 | $88.07M | $1B | $-241.88M | $-957.26M | $-178.52M | $1.55B |
Revenue by Products
| Product | Q1-2021 | Q2-2021 | Q3-2021 | Q4-2021 |
|---|---|---|---|---|
 Pharmaceutical Distribution | $50.49Bn ▲ | $47.10Bn ▼ | $49.31Bn ▲ | $51.25Bn ▲ |
Revenue by Geography
| Region | Q4-2025 | Q2-2025 | Q3-2025 | Q1-2025 |
|---|---|---|---|---|
 International Healthcare Solutions | $7.94Bn ▲ | $7.17Bn ▼ | $7.79Bn ▲ | $7.46Bn ▼ |
| US Healthcare Solutions | $75.79Bn ▲ | $68.28Bn ▼ | $72.88Bn ▲ | $74.03Bn ▲ |
CEO
Robert P. Mauch PharmD
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2014-06-13 | Forward | 10:1 |
| 2009-06-16 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 660
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
BLACKROCK FUND ADVISORS
Shares:2.78M
Value:$973.73M
SECURITY CAPITAL RESEARCH & MANAGEMENT INC
Shares:1.35M
Value:$473.12M
BLACKROCK INSTITUTIONAL TRUST COMPANY, N.A.
Shares:1.05M
Value:$368.37M
Summary
Showing Top 3 of 72